Literature DB >> 25870008

The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease.

Tamina Seeger-Nukpezah1, Daniel M Geynisman2, Anna S Nikonova3, Thomas Benzing4, Erica A Golemis3.   

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is a progressive inherited disorder in which renal tissue is gradually replaced with fluid-filled cysts, giving rise to chronic kidney disease (CKD) and progressive loss of renal function. ADPKD is also associated with liver ductal cysts, hypertension, chronic pain and extra-renal problems such as cerebral aneurysms. Intriguingly, improved understanding of the signalling and pathological derangements characteristic of ADPKD has revealed marked similarities to those of solid tumours, even though the gross presentation of tumours and the greater morbidity and mortality associated with tumour invasion and metastasis would initially suggest entirely different disease processes. The commonalities between ADPKD and cancer are provocative, particularly in the context of recent preclinical and clinical studies of ADPKD that have shown promise with drugs that were originally developed for cancer. The potential therapeutic benefit of such repurposing has led us to review in detail the pathological features of ADPKD through the lens of the defined, classic hallmarks of cancer. In addition, we have evaluated features typical of ADPKD, and determined whether evidence supports the presence of such features in cancer cells. This analysis, which places pathological processes in the context of defined signalling pathways and approved signalling inhibitors, highlights potential avenues for further research and therapeutic exploitation in both diseases.

Entities:  

Mesh:

Year:  2015        PMID: 25870008      PMCID: PMC5902186          DOI: 10.1038/nrneph.2015.46

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN: 1759-5061            Impact factor:   28.314


  273 in total

1.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.

Authors:  P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe
Journal:  Nature       Date:  1999-05-20       Impact factor: 49.962

2.  Polycystin 1 is required for the structural integrity of blood vessels.

Authors:  K Kim; I Drummond; O Ibraghimov-Beskrovnaya; K Klinger; M A Arnaout
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

3.  Molecular pathways: the role of primary cilia in cancer progression and therapeutics with a focus on Hedgehog signaling.

Authors:  Nadia B Hassounah; Thomas A Bunch; Kimberly M McDermott
Journal:  Clin Cancer Res       Date:  2012-03-13       Impact factor: 12.531

4.  PET imaging of glutaminolysis in tumors by 18F-(2S,4R)4-fluoroglutamine.

Authors:  Brian P Lieberman; Karl Ploessl; Limin Wang; Wenchao Qu; Zhihao Zha; David R Wise; Lewis A Chodosh; George Belka; Craig B Thompson; Hank F Kung
Journal:  J Nucl Med       Date:  2011-11-15       Impact factor: 10.057

Review 5.  The von Hippel-Lindau tumor suppressor gene and kidney cancer.

Authors:  William G Kaelin
Journal:  Clin Cancer Res       Date:  2004-09-15       Impact factor: 12.531

6.  Pkd1 haploinsufficiency increases renal damage and induces microcyst formation following ischemia/reperfusion.

Authors:  Ana P Bastos; Klaus Piontek; Ana M Silva; Dino Martini; Luis F Menezes; Jonathan M Fonseca; Ivone I Fonseca; Gregory G Germino; Luiz F Onuchic
Journal:  J Am Soc Nephrol       Date:  2009-10-15       Impact factor: 10.121

Review 7.  Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer.

Authors:  Woonyoung Choi; Bogdan Czerniak; Andrea Ochoa; Xiaoping Su; Arlene Siefker-Radtke; Colin Dinney; David J McConkey
Journal:  Nat Rev Urol       Date:  2014-06-24       Impact factor: 14.432

8.  HDAC6 inhibition restores ciliary expression and decreases tumor growth.

Authors:  Sergio A Gradilone; Brynn N Radtke; Pamela S Bogert; Bing Q Huang; Gabriella B Gajdos; Nicholas F LaRusso
Journal:  Cancer Res       Date:  2013-01-31       Impact factor: 12.701

Review 9.  Sorting out functions of sirtuins in cancer.

Authors:  M Roth; W Y Chen
Journal:  Oncogene       Date:  2013-04-22       Impact factor: 9.867

10.  A tumor necrosis factor-alpha-mediated pathway promoting autosomal dominant polycystic kidney disease.

Authors:  Xiaogang Li; Brenda S Magenheimer; Sheng Xia; Teri Johnson; Darren P Wallace; James P Calvet; Rong Li
Journal:  Nat Med       Date:  2008-06-15       Impact factor: 53.440

View more
  52 in total

1.  The cpk model of recessive PKD shows glutamine dependence associated with the production of the oncometabolite 2-hydroxyglutarate.

Authors:  Vicki J Hwang; Jeffrey Kim; Amy Rand; Chaozhe Yang; Steve Sturdivant; Bruce Hammock; P Darwin Bell; Lisa M Guay-Woodford; Robert H Weiss
Journal:  Am J Physiol Renal Physiol       Date:  2015-07-08

2.  Ganetespib limits ciliation and cystogenesis in autosomal-dominant polycystic kidney disease (ADPKD).

Authors:  Anna S Nikonova; Alexander Y Deneka; Anna A Kiseleva; Vladislav Korobeynikov; Anna Gaponova; Ilya G Serebriiskii; Meghan C Kopp; Harvey H Hensley; Tamina N Seeger-Nukpezah; Stefan Somlo; David A Proia; Erica A Golemis
Journal:  FASEB J       Date:  2018-01-10       Impact factor: 5.191

3.  Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease.

Authors:  Irfana Soomro; Ying Sun; Zhai Li; Lonnette Diggs; Georgia Hatzivassiliou; Ajit G Thomas; Rana Rais; Seth J Parker; Barbara S Slusher; Alec C Kimmelman; Stefan Somlo; Edward Y Skolnik
Journal:  Nephrol Dial Transplant       Date:  2018-08-01       Impact factor: 5.992

Review 4.  Polycystin and calcium signaling in cell death and survival.

Authors:  Fernanda O Lemos; Barbara E Ehrlich
Journal:  Cell Calcium       Date:  2017-05-24       Impact factor: 6.817

5.  Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease.

Authors:  Vicki J Hwang; Xia Zhou; Xiaonan Chen; Josephine Trott; Omran Abu Aboud; Kyuhwan Shim; Lai Kuan Dionne; Kenneth J Chmiel; William Senapedis; Erkan Baloglu; Moe R Mahjoub; Xiaogang Li; Robert H Weiss
Journal:  Kidney Int       Date:  2017-05-23       Impact factor: 10.612

6.  Arginine reprogramming in ADPKD results in arginine-dependent cystogenesis.

Authors:  Josephine F Trott; Vicki J Hwang; Tatsuto Ishimaru; Kenneth J Chmiel; Julie X Zhou; Kyuhwan Shim; Benjamin J Stewart; Moe R Mahjoub; Kuang-Yu Jen; Dinesh K Barupal; Xiaogang Li; Robert H Weiss
Journal:  Am J Physiol Renal Physiol       Date:  2018-10-03

7.  Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease.

Authors:  Kristen L Nowak; Zhiying You; Berenice Gitomer; Godela Brosnahan; Vicente E Torres; Arlene B Chapman; Ronald D Perrone; Theodore I Steinman; Kaleab Z Abebe; Frederic F Rahbari-Oskoui; Alan S L Yu; Peter C Harris; Kyongtae T Bae; Marie Hogan; Dana Miskulin; Michel Chonchol
Journal:  J Am Soc Nephrol       Date:  2017-11-08       Impact factor: 10.121

8.  Super-enhancer-driven metabolic reprogramming promotes cystogenesis in autosomal dominant polycystic kidney disease.

Authors:  Zeyun Mi; Yandong Song; Xinyi Cao; Yi Lu; Zhiheng Liu; Xu Zhu; Meijuan Geng; Yongzhan Sun; Bingxue Lan; Chaoran He; Hui Xiong; Lirong Zhang; Yupeng Chen
Journal:  Nat Metab       Date:  2020-07-13

Review 9.  Proliferative signaling by ERBB proteins and RAF/MEK/ERK effectors in polycystic kidney disease.

Authors:  Mitchell I Parker; Anna S Nikonova; Danlin Sun; Erica A Golemis
Journal:  Cell Signal       Date:  2019-12-09       Impact factor: 4.315

10.  Somatic Mutations in Renal Cyst Epithelium in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Adrian Y Tan; Tuo Zhang; Alber Michaeel; Jon Blumenfeld; Genyan Liu; Wanying Zhang; Zhengmao Zhang; Yi Zhu; Lior Rennert; Che Martin; Jenny Xiang; Steven P Salvatore; Brian D Robinson; Sandip Kapur; Stephanie Donahue; Warren O Bobb; Hanna Rennert
Journal:  J Am Soc Nephrol       Date:  2018-07-24       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.